ArticleNature communications2025

Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial.

Pavlos Msaouel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.